small nucleolar RNA, H/ACA box 58Genealiases: ACA58 · SNORA58B
Q-omics provides the consensus-scored SNORA58 profile across patient tissues and cancer cell-line models. SNORA58 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, SNORA58 is differentially expressed in 10, with the highest sampling consensus in BLCA. Additionally, SNORA58 RNA expression shows 12,283 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUAD, BLCA, and LSCC as cancer lineages where SNORA58 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA58 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA58 survival associations across molecular data types. SNORA58 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA58 RNA expression–survival associations across cancer types. High SNORA58 expression shows unfavorable associations in DLBC and KIRP, but favorable associations in LUAD, PAAD, OV and UCEC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for SNORA58 RNA expression.
This table summarizes SNORA58 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA58. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA58 shows lower tumor expression in PAAD and higher tumor expression in BLCA, HNSC, LUSC, BRCA and LIHC. The BLCA box plot shows higher SNORA58 RNA expression in tumor versus normal tissue (log2 FC = +0.663, t-test p = .001).
This table shows molecular features associated with SNORA58 in patient tissues and cancer cell lines. In patient samples, SNORA58 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
